Clinical efficacy of Jingyin granules, a Chinese patent medicine, in treating patients infected with coronavirus disease 2019.

ABSTRACT:

Background

Jingyin granules (JY), one patented Chinese herbal formula, have been advised for treating coronavirus disease 2019 (COVID-19) in China. As of now, the safety and effectiveness of JY in treating COVID-19 patients were still to be evaluated.

Purpose

To investigate the safety and clinical effectiveness of JY in treating mild COVID-19 patients.

Study design

We carried out a prospective cohort study, as the highly infectious COVID-19 omicron variant ranged in Shanghai (ClinicalTrial.gov registration number: ChiCTR2200058692).

Methods

Participants infected with COVID-19, who were diagnosed as mild cases, were assigned to receive either JY (JY group) or traditional Chinese medicine placebo (placebo group) orally for 7 days. The primary clinical indicators

SUBMITTER: Chen B 

PROVIDER: S-EPMC9575312 | biostudies-literature | 2022 Oct

REPOSITORIES: biostudies-literature